

Ni(II)-catalyzed dehydrative alkynylation of unactivated (hetero)aryl C–H bonds using oxygen: an user-friendly approach

Yan-Hua Liu, Yue-Jin Liu, Sheng-Yi Yan, and Bing-Feng Shi*

Department of Chemistry, Zhejiang University, Hangzhou 310027, China

Supporting Information

Table of Contents:

1. General information	S2
2. Experimental Section	S3
2.1 Preparation of Substrates	S3
2.2 Optimization of Reaction Conditions	S4
2.3 General Procedure for the Alkynylation	S10
2.4 Procedure for Intramolecular Aminoalkynylation of 2a	S21
2.5 Mechanism Investigation	S24
3. References	S26
4. NMR Spectra	S27

1. General Information


Trimethylacetonitrile was dried by Sodium, distilled under reduced pressure and stored under nitrogen. NiI_2 was obtained from *Alfa Aesar*[®]. The other materials and solvents were purchased from Adamas and other commercial suppliers and used without additional purification. NMR spectra were recorded on a Bruke Avance operating for ^1H NMR at 400 MHz, ^{13}C NMR at 100 MHz using TMS as internal standard. The peaks were internally referenced to TMS (0.00 ppm) or residual undeuterated solvent signal (77.16 ppm for ^{13}C NMR). The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, m = multiplet, b = broad. Mass spectroscopy data of the products were collected on an HRMS-TOF instrument or a low-resolution MS instrument using EI ionization.

2. Experimental Section


2.1 Preparation of Substrates

Compounds **1a-1z**, **d₅-1m**, **5a** were known compounds.^[1-6] Compounds **4a** were prepared following typical method A.

General Procedure for the Preparation of Starting Materials (Method A):



A solution of acid (5 mmol) was refluxed in 5 mL SOCl₂ for 2h and cooled to RT. The excess of SOCl₂ was removed under vacuum to give corresponding acid chloride. The acid chloride was then re-dissolved in 5 mL dry CH₂Cl₂ and added dropwise to a 20 mL dry CH₂Cl₂ solution containing amine (5 mmol) and Et₃N (10 mmol) at 0 °C. After stirring for 6h at ambient temperature, the resulting mixture was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give the desired product.




2-iodo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide **4a**

The title compound **4a** was prepared according to the general procedure (Method A).

¹H NMR (400 MHz, CDCl₃) δ 8.47 (d, *J* = 3.6 Hz, 1H), 8.19 (s, 1H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.74 (t, *J* = 7.8 Hz, 1H), 7.51 – 7.43 (m, 2H), 7.38 (t, *J* = 7.4 Hz, 1H), 7.23 – 7.16 (m, 1H), 7.08 (t, *J* = 7.6 Hz, 1H), 1.91 (s, 6H). **¹³C NMR** (100 MHz, CDCl₃) δ 168.83, 164.41, 147.85, 143.73, 140.14, 137.52, 130.96, 128.45, 128.42, 122.29, 119.84, 92.97, 57.62, 27.73. **HRMS** (EI-TOF) calc. for C₁₅H₁₅IN₂O (M⁺): 366.0229, found: 366.0233.

2.2 Optimization of Reaction Conditions


Screening of Ni Catalysts



Entry ^a	Ni(II)	Yield(%) ^b 2a/3a
1	Ni(OTf) ₂	10/0
2	Ni(acac) ₂	18/0
3	Ni(OAc) ₂	19/0
4	NiI ₂	37/0
5	NiBr ₂	trace/0

^a Reaction conditions unless noted: **1a** (0.1 mmol), alkyne (0.15 mmol), Ni(II) (0.01 mmol), DME (0.02 mmol), Na₂CO₃ (0.2 mmol), 1 atm O₂, *n*-PrCN (0.5 mL), 140°C, 12 h. ^b Determined by ¹H NMR analysis of the crude reaction mixtures using CH₂Br₂ as internal standard based on two parallel reactions.


Screening of Solvents



Entry ^a	Solvent	Yield(%) ^b 2a/3a
1	CH_2CN	0/0
2	<i>t</i> -BuCN	38/6
3	Toluene	28/0
4	<i>o</i> -xylene	0/0
5	DMSO	trace/0
6	DCE	trace/0

^a Reaction conditions unless noted: **1a** (0.1 mmol), alkyne (0.15 mmol), Ni(II) (0.01 mmol), DME (0.02 mmol), Na_2CO_3 (0.2 mmol), 1 atm O_2 , Solvent (0.5 mL), 140°C , 12 h. ^b Determined by ^1H NMR analysis of the crude reaction mixtures using CH_2Br_2 as internal standard based on two parallel reactions.


Screening of Bases



Entry ^a	Base	Yield(%) ^b 2a/3a
1	Li_2CO_3	39/trace
2	KHCO_3	32/7
3	NaHCO_3	41/17
4	KH_2PO_4	47/20
5	LiOAc	32/7
6	NaOAc	trace/0
7	--	32/16
8	$\text{NaHCO}_3:\text{NaH}_2\text{PO}_4=1:1$	47/15
9	$\text{NaHCO}_3:\text{Li}_2\text{CO}_3=1:1$	45/16
10	MgSO_4	40/17
11	CaCl_2	44/14

^a Reaction conditions unless noted: **1a** (0.1 mmol), alkyne (0.15 mmol), Ni(II) (0.01 mmol), DME (0.02 mmol), Base (0.2 mmol), 1 atm O_2 , $t\text{-BuCN}$ (0.5 mL), 140°C , 12 h. ^b Determined by ^1H NMR analysis of the crude reaction mixtures using CH_2Br_2 as internal standard based on two parallel reactions.


Screening of Ligands



Entry ^a	Ligand	Yield(%) ^b 2a/3a
1	DME	41/17
2	DPPP	42/10
3	BINAP	47/17
4	1,10-Phen	<20/0
5	2,2'-Bipyridine	<20/0
6	BINOL	trace/0
7 ^c	DME	41/5
8 ^c	1,2-Dimethoxybenzene	48/5
9 ^c	1,2-Bis(phenylthio)ethane	43/10
10 ^c	S(<i>i</i> -Pr) ₂	48/14
11 ^c	SMe ₂	34/trace
12 ^c	COD	36/5
13 ^c	18-Crown-6	45/trace
14 ^c	digylme	32/trace

^a Reaction conditions unless noted: **1a** (0.1 mmol), alkyne (0.15 mmol), Ni(II) (0.01 mmol), Ligand (0.02 mmol), NaHCO₃ (0.2 mmol), 1 atm O₂, *t*-BuCN (0.5 mL), 140°C, 12 h. ^b Determined by ¹H NMR analysis of the crude reaction mixtures using CH₂Br₂ as internal standard based on two parallel reactions. ^c alkyne (0.1 mmol).


Screening of the equivalences of alkyne



Entry ^a	alkyne (mmol)	Yield(%) ^b 2a/3a
1	0.5	40/7
2	1.0	38/4
3	1.5	40/9
4	2.0	42/13

^a Reaction conditions unless noted: **1a** (0.1 mmol), alkyne (X mmol), Ni(II) (0.01 mmol), DME (0.02 mmol), NaCO_3 (0.2 mmol), 1 atm O_2 , $t\text{-BuCN}$ (0.5 mL), 140°C , 12 h. ^b Determined by ^1H NMR analysis of the crude reaction mixtures using CH_2Br_2 as internal standard based on **1a** of two parallel reactions.


Influences of Bases, Ligands and equivalences of 1a




Entry ^a	NaHCO ₃ (mmol)	DME(mmol)	Yield(%) ^b
			2a/3a
1	0.2	0.02	40/7
2	0.2	0	53/6
3	0	0	52/6
4 ^c	0	0	61/6
5 ^d	0	0	73/6
6 ^{d,f}	0	0	87 ^g /trace
7 ^{e,f}	0	0	87/trace

^a Reaction conditions unless noted: **1a** (0.1 mmol), alkyne (0.1 mmol), Ni(II) (0.01 mmol), DME (0.02 mmol), NaHCO₃ (0.2 mmol), 1 atm O₂, *t*-BuCN (0.5 mL), 140 °C, 12 h, two parallel reactions were conducted. ^b Determined by ¹H NMR analysis of the crude reaction mixtures using CH₂Br₂ as internal standard based on **alkyne**. ^c **1a** (0.12 mmol). ^d **1a** (0.15 mmol). ^e **1a** (0.20 mmol). ^f 0.1 mmol of NaI was added. ^g isolated yield.


Influences of Directing Group



2.3 General Procedure for Alkynylation




To an oven-dried 50 mL screw-capped vial was added substrate **1** (0.15 mmol), Triisopropylsilylacetylene (22.4 μL , 0.1 mmol), NiI_2 (3.12 mg, 0.01 mmol), NaI (14.9 mg, 0.1 mmol), $t\text{-BuCN}$ (0.5 mL). Two parallel reactions were conducted. The mixture was stirred for 12 h (for aromatic amides) or 18 h (for heteroaromatic amides) at 140 °C under O_2 followed by cooling. Both resulting mixtures were diluted with 40ml dichloromethane, combined together, filtered through a celite pad and concentrated in vacuo. The residue was purified by flash chromatography using petroleum ether/ethyl acetate as the eluent to afford the product.




2-Methyl-N-(2-(Pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide **2a**^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, *J* = 4.4 Hz, 1H), 8.15 (s, 1H), 7.71 (t, *J* = 7.2 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 7.36 (d, *J* = 7.2 Hz, 1H), 7.22 – 7.13 (m, 3H), 2.37 (s, 3H), 1.92 (s, 6H), 1.03 – 0.96 (m, 21H).




2-Fluoro-*N*-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide 2b^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, *J* = 4.0 Hz, 1H), 8.28 (s, 1H), 7.72 (td, *J* = 8.0, 2.0 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 7.34 – 7.30 (m, 1H), 7.28 – 7.24 (m, 1H), 7.17 (d, *J* = 6.4, 4.8 Hz, 1H), 7.07 (td, *J* = 8.4 Hz, 0.8 Hz, 1H), 1.90 (s, 6H), 1.05 – 0.98 (m, 21H).




4-Nitro-*N*-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide 2c^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.64 (s, 1H), 8.48 (d, *J* = 4.4 Hz, 1H), 8.35 (d, *J* = 2.4 Hz, 1H), 8.18 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.85 (d, *J* = 8.4 Hz, 1H), 7.73 (td, *J* = 7.6, 1.2 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.20 (dd, *J* = 7.0, 5.0 Hz, 1H), 1.89 (s, 6H), 1.05 (s, 21H).




***N*-(2-(Pyridin-2-yl)propan-2-yl)-5-(trifluoromethyl)-2-((triisopropylsilyl)ethynyl)benzamide 2d^[6]**

¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 8.41 (d, *J* = 4.0 Hz, 1H), 7.72 (m, 2H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.42 (m, 2H), 7.17 (dd, *J* = 6.8, 5.2 Hz, 1H), 1.91 (s, 6H), 1.03 – 0.97 (m, 21H).




4-Chloro-*N*-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide 2e^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 4.0 Hz, 1H), 8.43 (s, 1H), 7.74 – 7.66 (m, 2H), 7.51 (d, *J* = 1.5 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.34 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.16 (dd, *J* = 6.4, 4.8 Hz, 1H), 1.86 (s, 6H), 1.06 – 1.00 (m, 21H).




4-iodo-*N*-(2-(pyridin-2-yl)propan-2-yl)-6-((triisopropylsilyl)ethynyl)benzamide 2f

¹H NMR (400 MHz, CDCl₃) δ 8.49 (d, *J* = 4.1 Hz, 1H), 8.42 (s, 1H), 7.88 (d, *J* = 1.6 Hz, 1H), 7.69 (m, 2H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.43 (d, *J* = 8.0 Hz, 1H), 7.16 (dd, *J* = 6.8, 5.2 Hz, 1H), 1.85 (s, 6H), 1.06 – 1.00 (m, 21H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.56, 164.37, 147.98, 142.68, 137.65, 136.89, 130.49, 122.00, 121.71, 119.32, 103.51, 98.88, 95.50, 57.66, 27.63, 18.63, 11.27. **HRMS** (EI-TOF) calc. for C₂₆H₃₅IN₂OSi (M⁺): 546.1563, found: 546.1558.




***N*-(2-(pyridin-2-yl)propan-2-yl)-5-(trifluoromethyl)-2-((triisopropylsilyl)ethynyl)benzamide 2g^[6]**

¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1H), 8.50 (d, *J* = 4.8 Hz, 1H), 8.05 (s, 1H), 7.70 (td, *J* = 8.0, 2.0 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 7.18 (dd, *J* = 6.9, 4.2 Hz, 1H), 1.88 (s, 6H), 1.12 – 0.96 (m, 21H).




N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)-[1,1'-biphenyl]-2-carboxamide **2h^[6]**

¹H NMR (400 MHz, CDCl₃) δ 8.35 (d, *J* = 4.0 Hz, 1H), 7.86 (s, 1H), 7.58 (td, *J* = 7.6, 1.4 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.47 (d, *J* = 6.0 Hz, 2H), 7.36 (t, *J* = 7.6 Hz, 1H), 7.24-7.31 (m, 4H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.09 (dd, *J* = 7.2, 4.8 Hz, 1H), 1.59 (s, 6H), 1.13 – 0.93 (m, 21H).




4-((2-(pyridin-2-yl)propan-2-yl)carbamoyl)-3-((triisopropylsilyl)ethynyl)phenyl acetate **2i**

¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 4.0 Hz, 1H), 8.41 (s, 1H), 7.81 (d, *J* = 8.8 Hz, 1H), 7.67 (td, *J* = 8.0, 2.0 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.17 - 7.10 (m, 2H), 2.32 (s, 3H), 1.86 (s, 6H), 1.06 (s, 21H). ¹³C NMR (100 MHz, CDCl₃) δ 168.99, 165.51, 164.45, 151.31, 148.01, 136.83, 135.74, 130.64, 127.20, 122.32, 121.65, 119.30, 104.21, 98.34, 77.37, 77.05, 76.73, 57.68, 27.69, 21.08, 18.63, 11.26. HRMS (EI-TOF) calc. for C₂₈H₃₈N₂O₃Si (M⁺): 478.2652, found: 478.2652.




5-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide **2j^[5]**

¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 4.0 Hz, 1H), 8.45 (s, 1H), 7.92 (d, *J* = 2.0 Hz, 1H), 7.69 (td, *J* = 7.6, 2.0 Hz, 1H), 7.48 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.16 (dd, *J* = 6.4, 6.2 Hz, 1H), 1.86 (s, 6H), 1.00 - 1.06 (m, 21H)




5-methoxy-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide **2k**

¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, *J* = 4.0 Hz, 1H), 8.47 (s, 1H), 7.66 (t, *J* = 7.6 Hz, 1H), 7.48 (m, 2H), 7.39 (s, 1H), 7.20 – 7.11 (m, 1H), 6.92 (dd, *J* = 8.2, 1.6 Hz, 1H), 3.82 (s, 3H), 1.86 (s, 6H), 1.27 – 0.97 (m, 21H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.71, 164.70, 159.93, 148.28, 138.76, 136.81, 136.44, 121.66, 119.41, 117.41, 113.43, 112.34, 105.70, 96.08, 57.93, 55.66, 27.94, 18.77, 11.43. **HRMS** (EI-TOF) calc. for C₂₇H₃₈N₂O₂Si(M⁺): 450.2703, found: 450.2701.




N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)-2-naphthamide 2l^[5]

¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, *J* = 4.0 Hz, 1H), 8.48 (s, 1H), 8.32 (s, 1H), 8.09 (s, 1H), 7.86 (d, *J* = 7.2 Hz, 1H), 7.80 (d, *J* = 7.6 Hz, 1H), 7.69 (td, *J* = 7.9, 1.6 Hz, 1H), 7.56 – 7.48 (m, 3H), 7.16 (dd, *J* = 6.4, 4.8 Hz, 1H), 1.91 (s, 6H), 1.11 – 1.00 (m, 21H).




N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 2m^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.50 (d, *J* = 4.4 Hz, 1H), 8.38 (s, 1H), 7.80 (dd, *J* = 6.4, 4.0 Hz, 1H), 7.67 (td, *J* = 8.0, 2.0 Hz, 1H), 7.57 (dd, *J* = 6.0, 2.8 Hz, 1H), 7.47 (d, *J* = 8.0 Hz, 1H), 7.41 – 7.33 (m, 2H), 7.15 (dd, *J* = 6.8, 5.6 Hz, 1H), 1.87 (s, 6H), 1.13 – 0.96 (m, 21H).




4-methoxy-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)benzamide 2n^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, *J* = 4.4 Hz, 1H), 8.32 (s, 1H), 7.84 (d, *J* = 8.8 Hz, 1H), 7.65 (td, *J* = 7.8, 1.6 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.13 (dd, *J* = 7.0, 5.4 Hz, 1H), 7.04 (d, *J* = 2.4 Hz, 1H), 6.91 (dd, *J* = 8.8, 2.8 Hz, 1H), 3.84 (s, 3H), 1.84 (s, 6H), 1.13 – 1.00 (m, 21H).




N-(2-(pyridin-2-yl)propan-2-yl)-7-((triisopropylsilyl)ethynyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 2o^[5]

¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, *J* = 4.0 Hz, 1H), 8.33 (s, 1H), 7.65 (td, *J* = 8.0, 1.6 Hz, 1H), 7.49 – 7.38 (m, 2H), 7.13 (dd, *J* = 7.0, 5.2 Hz, 1H), 7.05 (s, 1H), 4.26 (s, 4H), 1.83 (s, 6H), 1.11 – 1.01 (m, 21H).




N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)isonicotinamide 2p^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 8.60 (m, 2H), 8.49 (dd, *J* = 4.0, 0.8 Hz, 1H), 7.71 (td, *J* = 8.0, 1.76 Hz, 1H), 7.63 (d, *J* = 4.8 Hz, 1H), 7.45 (d, *J* = 8.1 Hz, 1H), 7.22 – 7.14 (m, *J* = 6.6, 5.2 Hz, 1H), 1.87 (s, 6H), 1.15 – 0.94 (m, 21H).




2-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 2q^[5]

¹H NMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 8.51 (s, 1H), 8.49 (d, *J* = 4.8 Hz, 1H), 7.79 (s, 1H), 7.73 (td, *J* = 7.6, 1.4 Hz, 1H), 7.43 (d, *J* = 8.0 Hz, 1H), 7.20 (dd, *J* = 7.0, 5.2 Hz, 1H), 1.86 (s, 6H), 1.16 – 0.95 (m, 21H).




3-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 2r^[5]

¹H NMR (400 MHz, CDCl₃) δ 8.62 (s, 1H), 8.56 (s, 1H), 8.54 (s, 1H), 8.44 (d, *J* = 4.4 Hz, 1H), 7.75 (td, *J* = 8.0, 1.6 Hz, 1H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.20 (dd, *J* = 6.8, 5.2 Hz, 1H), 1.92 (s, 6H), 0.97 -1.04 (m, 21H).




2-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 2s^[5]

¹H NMR (400 MHz, CDCl₃) δ 8.68 (s, 1H), 8.56 (s, 1H), 8.50 (d, *J* = 4.4 Hz, 1H), 7.70 (td, *J* = 8.0, 1.6 Hz, 1H), 7.50 (s, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.18 (dd, *J* = 7.2, 5.6 Hz, 1H), 2.58 (s, 3H), 1.86 (s, 6H), 1.12 – 0.91 (m, 21H).



5-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)nicotinamide 2t^[5]

¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 1H), 8.52 – 8.44 (m, 2H), 7.86 (s, 1H), 7.70 (td, *J* = 8.0, 2.0 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.17 (dd, *J* = 7.2, 5.6 Hz, 1H), 2.36 (s, 3H), 1.87 (s, 6H), 1.21 – 0.93 (m, 21H).




2-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-4-((triisopropylsilyl)ethynyl)nicotinamide 2u

¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 8.45 (d, *J* = 4.0 Hz, 1H), 8.16 (d, *J* = 4.8 Hz, 1H), 7.74 (t, *J* = 8.0 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.29 (d, *J* = 4.8 Hz, 1H), 7.25 – 7.14 (m, 1H), 1.90 (s, 6H), 1.03 (m, 21H). **¹³C NMR** (100 MHz, CDCl₃) δ 163.77, 160.15 (d, *J* = 237.6 Hz), 161.08 (d, *J* = 3.8 Hz), 158.97, 147.38, 147.26 (d, *J* = 16 Hz), 137.29, 133.51 (d, *J* = 5.8 Hz), 125.44 (d, *J* = 4.3 Hz),


122.08 (d, $J = 34.7$ Hz), 122.00, 119.37, 102.72, 100.83 (d, $J = 5.2$ Hz), 57.51, 27.37, 18.52, 11.12.

HRMS (EI-TOF) calc. for $C_{25}H_{34}FN_3OSi(M^+)$: 439.2455, found: 439.2449




2-chloro-N-(2-(pyridin-2-yl)propan-2-yl)-4-((triisopropylsilyl)ethynyl)nicotinamide 2v^[5]

¹H NMR (400 MHz, $CDCl_3$) δ 8.51 (s, 1H), 8.45 (d, $J = 4.0$ Hz, 1H), 8.33 (d, $J = 4.8$ Hz, 1H), 7.74 (td, $J = 8.0, 1.6$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.33 (d, $J = 5.2$ Hz, 1H), 7.21 (dd, $J = 6.8, 4.8$ Hz, 1H), 1.92 (s, 6H), 1.01 - 1.05 (m, 21H).




2-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-4-((triisopropylsilyl)ethynyl)nicotinamide 2w

¹H NMR (400 MHz, $CDCl_3$) δ 8.44 (d, $J = 4.8$ Hz, 2H), 8.39 (br, 1H), 7.74 (td, $J = 8.0, 1.6$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.23 - 7.18 (m, 2H), 2.61 (s, 3H), 1.92 (s, 6H), 1.03 - 0.98 (m, 21H). **¹³C NMR** (100 MHz, $CDCl_3$) δ 166.23, 164.07, 156.03, 148.63, 147.54, 137.33, 134.26, 128.77, 124.72, 122.09, 119.51, 102.39, 99.98, 57.33, 27.43, 22.70, 18.65, 11.27. **HRMS** (EI-TOF) calc. for $C_{26}H_{37}N_3OSi(M^+)$: 435.2706, found: 435.2700




N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)thiophene-3-carboxamide 2x^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.54 (d, *J* = 4.0 Hz, 1H), 8.05 (s, 1H), 7.65 (dd, *J* = 8.0, 2.0 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.41 (d, *J* = 5.2 Hz, 1H), 7.10 - 7.15 (m, *J* = 6.4, 2H), 1.82 (s, 6H), 1.0 - 1.10 (m, 21H).




2-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-5-((triisopropylsilyl)ethynyl)isonicotinamide 2ya

¹H NMR (400 MHz, CDCl₃) δ 8.69 (s, 1H), 8.49 (d, *J* = 4.0 Hz, 1H), 8.43 (s, 1H), 7.73 (td, *J* = 8.0, 1.6 Hz, 1H), 7.43 (d, *J* = 8.0 Hz, 1H), 7.27 (d, *J* = 2.0 Hz, 1H), 7.19 (dd, *J* = 6.8, 4.8 Hz, 1H), 1.87 (s, 6H), 1.14 - 0.93 (m, 21H). **¹³C NMR** (100 MHz, CDCl₃) δ 163.72, 163.12 (d, *J* = 242.3 Hz), 163.03 (d, *J* = 2.9 Hz), 152.18 (d, *J* = 14.7 Hz), 150.05 (d, *J* = 7.8 Hz), 147.89, 137.15, 121.99, 119.29, 114.82 (d, *J* = 5.1 Hz), 108.71 (d, *J* = 39 Hz), 100.27, 100.44, 57.81, 27.42, 18.57, 11.19. **HRMS** (EI-TOF) calc. for C₂₅H₃₄FN₃OSi (M⁺): 439.2455, found: 439.2449.




2-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-3-((triisopropylsilyl)ethynyl)isonicotinamide 2yb^[6]

¹H NMR (400 MHz, CDCl₃) δ 8.71 (s, 1H), 8.49 (d, *J* = 4.0 Hz, 1H), 8.18 (d, *J* = 5.2 Hz, 1H), 7.73 (td, *J* = 8.0, 1.6 Hz, 1H), 7.50 (d, *J* = 5.2 Hz, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 7.20 (dd, *J* = 6.4, 5.0 Hz, 1H), 1.88 (s, 6H), 1.04 (s, 21H).




6-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-4-((triisopropylsilyl)ethynyl)nicotinamide 2za

¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H), 8.54 (s, 1H), 8.49 (d, *J* = 4.4 Hz, 1H), 7.73 (td, *J* = 8.0, 1.6 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 1H), 7.20 (dd, *J* = 6.6, 5.0 Hz, 1H), 7.02 (d, *J* = 2.0 Hz, 1H), 1.87 (s, 6H), 1.13 – 0.94 (m, 21H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.02, 163.54, 163.98 (d, *J* = 240.4 Hz), 149.13 (d, *J* = 16.3 Hz), 147.80, 137.18, 133.46 (d, *J* = 9.8 Hz), 131.40 (d, *J* = 4.8 Hz), 121.95, 119.36, 113.20 (d, *J* = 38.4 Hz), 104.54, 101.28 (d, *J* = 3.9 Hz), 57.63, 27.48, 18.54, 11.15. **HRMS** (EI-TOF) calc. for C₂₅H₃₄FN₃OSi(M⁺): 439.2455, found: 439.2448.



6-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)-2-((triisopropylsilyl)ethynyl)nicotinamide 2zb


¹H NMR (400 MHz, CDCl₃) δ 8.62 (s, 1H), 8.50 (d, *J* = 4.4 Hz, 1H), 8.16 (t, *J* = 8.0 Hz, 1H), 7.72 (t, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.24 – 7.15 (m, 1H), 6.94 (dd, *J* = 8.4, 2.8 Hz, 1H), 1.87 (s, 6H), 1.20 – 0.93 (m, 21H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.05, 164.01, 162.78 (d, *J* = 242.9 Hz), 147.94, 142.72 (d, *J* = 8.7 Hz), 137.37 (d, *J* = 16.5 Hz), 137.0, 132.84 (d, *J* = 4.5 Hz), 121.89, 119.30, 109.81 (d, *J* = 37.4 Hz), 102.99, 99.27, 57.73, 27.50, 18.59, 11.26. **HRMS** (EI-TOF) calc. for C₂₅H₃₄FN₃OSi(M⁺): 439.2455, found: 439.2449.



2-((tert-butyldimethylsilyl)ethynyl)-6-methyl-N-(2-(pyridin-2-yl)propan-2-yl)benzamide 4a


¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, *J* = 4.8 Hz, 1H), 8.12 (s, 1H), 7.72 (td, *J* = 7.6, 1.6 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.35 (d, *J* = 6.8 Hz, 1H), 7.22 – 7.12 (m, 3H), 2.38 (s, 3H), 1.92 (s, 6H), 0.91 (s, 9H), 0.03 (s, 6H). **¹³C NMR** (100 MHz, CDCl₃) δ 167.63, 164.49, 147.63, 140.37, 137.15, 135.66,

130.95, 130.68, 128.32, 121.92, 120.37, 119.59, 103.77, 95.82, 77.48, 77.16, 76.84, 57.31, 27.62, 26.23, 19.51, 16.84, -4.61. **HRMS** (EI-TOF) calc. for C₂₄H₃₂N₂OSi (M⁺) :392.2284, found: 392.2279



2-methyl-N-(2-(pyridin-2-yl)propan-2-yl)-6-((triethylsilyl)ethynyl)benzamide 4b


¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, *J* = 3.6 Hz, 1H), 8.10 (s, 1H), 7.72 (t, *J* = 8.0 Hz, 1H), 7.48 (d, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 7.2 Hz, 1H), 7.23 – 7.06 (m, 3H), 2.37 (s, 3H), 1.92 (s, 6H), 0.92 (t, *J* = 7.8 Hz, 9H), 0.55 (q, *J* = 8.0 Hz, 6H). **¹³C NMR** (100 MHz, CDCl₃) δ 167.69, 164.50, 147.64, 140.38, 137.12, 135.61, 131.04, 130.62, 128.30, 121.91, 120.42, 119.58, 104.28, 95.05, 77.48, 76.84, 57.30, 27.55, 19.47, 7.52, 4.43. **HRMS** (EI-TOF) calc. for C₂₄H₃₂N₂OSi (M⁺) :392.2284, found: 392.2276




N-(quinolin-8-yl)-2-((triisopropylsilyl)ethynyl)benzamide 5

¹H NMR (400 MHz, CDCl₃) δ 10.49 (s, 1H), 8.92 (d, *J* = 7.2 Hz, 1H), 8.76 (dd, *J* = 4.0, 1.2 Hz, 1H), 8.16 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.80 (dd, *J* = 5.4, 3.4 Hz, 1H), 7.66 – 7.51 (m, 3H), 7.48 – 7.39 (m, 3H), 0.80 - 0.84 (m, 21H). **¹³C NMR** (100 MHz, CDCl₃) δ 166.44, 148.25, 139.26, 138.92, 136.19, 134.69, 133.91, 130.12, 128.68, 127.92, 127.36, 121.85, 121.46, 120.76, 117.15, 103.88, 97.16, 18.31, 11.07. **HRMS** (EI-TOF) calc. for C₂₇H₃₂N₂OSi(M⁺) :428.2284, found: 428.2280.

2.4 Procedure for Intramolecular Aminoalkynylation of **2a**



To an oven-dried 50 mL screw-capped vial was added **2a** (0.10mmol), Triisopropylsilylacetylene (34 μL , 0.15 mmol), NiI_2 (3.12 mg, 0.01 mmol), $t\text{-BuCN}$ (0.5 mL). The mixture was stirred for 18 h at 160°C under O_2 followed by cooling. The resulting mixture was diluted with 40 mL dichloromethane, filtered through a celite pad and concentrated in vacuo. The residue was purified by preparative TLC using petroleum ether/ethyl acetate as the eluent to afford the product.



(Z)-3-(1, 3-bis(triisopropylsilyl)prop-2-yn-1-ylidene)-7-methylisoindolin-1-one **3a**

$^1\text{H NMR}$ (400 MHz, $(\text{CD}_3)_2\text{CO}$) δ 9.02 (d, $J = 8.0$ Hz, 1H), 7.99 (s, 1H), 7.55 (t, $J = 7.8$ Hz, 1H), 7.39 (d, $J = 7.2$ Hz, 1H), 2.66 (s, 3H), 1.84 – 1.65 (m, 3H), 1.34 – 0.99 (m, 39H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 168.59, 148.96, 137.66, 137.54, 132.18, 126.30, 123.36, 108.23, 103.22, 98.56, 77.48, 77.16, 76.84, 18.81, 18.80, 17.72, 12.95, 11.80, 1.16. **HRMS** (EI-TOF) calc. for $\text{C}_{30}\text{H}_{49}\text{NOSi}_2$ (M^+): 495.3353, found: 495.3352.




Figure 1. ORTEP diagram of compound 3a.

Bond precision: C-C = 0.0135 Å Wavelength=0.71073

Cell: a=12.5020(8) b=15.8137(9) c=17.4136(10)
 alpha=74.497(2) beta=75.487(1) gamma=76.750(2)

Temperature: 296 K

	Calculated	Reported
Volume	3162.7(3)	3162.7(3)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C30 H49 N O Si2	?
Sum formula	C30 H49 N O Si2	C30 H49 N O Si2
Mr	495.88	495.88
Dx,g cm-3	1.041	1.041
Z	4	4

Mu (mm-1)	0.133	0.133
F000	1088.0	1088.0
F000'	1088.97	
h,k,lmax	14,18,20	14,18,20
Nref	11150	11075
Tmin,Tmax	0.944,0.963	0.943,0.964
Tmin'	0.942	

Correction method= # Reported T Limits: Tmin=0.943 Tmax=0.964

AbsCorr = MULTI-SCAN


Data completeness= 0.993 Theta(max)= 25.000

R(reflections)= 0.1479 (5124) wR2(reflections)= 0.4410 (11075)

S = 1.191 Npar= 569


2.5 Mechanism Investigation

Intermolecular Competition KIE



To an oven-dried 50 mL screw-capped vial was added substrate **1m** (0.075mmol), **d₅-1m** (0.075mmol), Triisopropylsilylacetylene (22.4 uL, 0.1mmol), NiI_2 (3.12 mg, 0.01mmol), NaI (14.9 mg, 0.1 mmol), $t\text{-BuCN}$ (0.5 mL). The mixture was stirred for 3h at 140°C under O_2 followed by cooling. The resulting mixture was diluted with 40mL dichloromethane, filtered through a celite pad and concentrated in vacuo. The residue was purified by preparative TLC using petroleum ether/ethyl acetate as the eluent to afford the product. The ratio of product **2m**/**[d₄]2m** was determined by ^1H NMR analysis using CH_2Br_2 as internal standard.

Intramolecular Competition KIE




To an oven-dried 50 mL screw-capped vial was added substrate **o-d-1m** (0.15mmol), Triisopropylsilylacetylene (22.4 uL, 0.1mmol), NiI_2 (3.12 mg, 0.01mmol), NaI (14.9 mg, 0.1 mmol), $t\text{-BuCN}$ (0.5 mL). The mixture was stirred for 3h at 140°C under O_2

followed by cooling. The resulting mixture was diluted with 40mL dichloromethane, filtered through a celite pad and concentrated in vacuo. The residue was purified by preparative TLC using petroleum ether/ethyl acetate as the eluent to afford the product. The ratio of product **[d₁]2m/2m** was determined by ¹H NMR analysis using CH₂Br₂ as internal standard.


3. References

1. Y. Aihara, N. Chatani, *J. Am. Chem. Soc.*, 2013, **135**, 5308.
2. F.-J. Chen, G. Liao, X. Li, J. Wu, B.-F. Shi, *Org. Lett.*, 2014, **16**, 5644.
3. X. Li, Y.-H. Liu, Yan-Hua, W.-J. Gu, B. Li, F.-J. Chen, B.-F. Shi, *Org. Lett.*, 2014, **16**, 3904.
4. B. Li, B. Liu, B.-F. Shi, *Chem. Commun.*, 2015, **51**, 5093.
5. Y.-J. Liu, Y.-H. Liu, S.-Y. Yan, B.-F. Shi, *Chem. Commun.*, 2015, **51**, 6388.
6. Y.-J. Liu, Y.-H. Liu, X.-S. Yin, W.-J. Gu and B.-F. Shi, *Chem. Eur. J.*, 2015, **21**, 205.


2c




2d




2e




2f




2h




2i








2j




2k




2l




2m




2n




2o




2p




2q




2r




2s




2t




2u








2v




2w





2x





2yb





2ya





2za





2zb





3a



4a



4b



5

